![Katie Ellias](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Katie Ellias
Directeur/Bestuurslid bij
SAB BIOTHERAPEUTICS, INC.
Profiel
Katie Ellias currently works at SAB Biotherapeutics, Inc., as Independent Director from 2023.
Ms. Ellias also formerly worked at Capillary Biomedical LLC, as Director from 2019 to 2022, Endeavour Vision SA, as Investment Director from 2016 to 2017, A Breakthrough T1D Venture LLC, as Managing Director from 2018 to 2024, Veralox Therapeutics, Inc., as Director, I2o Therapeutics, Inc., as Director, DiogenX SAS, as Director, Sofinnova Partners SAS, as Principal from 2011 to 2016, and Tech Health Experts, as Consultant from 2017 to 2018.
Ms. Ellias received her undergraduate degree in 2000 from Yale University and Masters Business Admin degree in 2006 from The Wharton School of the University of Pennsylvania.
Actieve functies van Katie Ellias
| Bedrijven | Functie | Begin |
|---|---|---|
| SAB BIOTHERAPEUTICS, INC. | Directeur/Bestuurslid | 20-11-2023 |
Eerdere bekende functies van Katie Ellias
| Bedrijven | Functie | Einde |
|---|---|---|
JDRF T1D Fund
 JDRF T1D Fund Investment ManagersFinance T1D Fund invests in companies located across the globe. The firm focuses on health technology sector. It participates in early stage capital requirements. | Private Equity Investor | 01-11-2024 |
Capillary Biomedical LLC
 Capillary Biomedical LLC Medical SpecialtiesHealth Technology Develops medical devices for diabetes management | Directeur/Bestuurslid | 01-07-2022 |
Tech Health Experts
 Tech Health Experts Information Technology ServicesTechnology Services Provides technical support services | Consultant / Adviseur | 30-07-2018 |
Endeavour Vision SA
 Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired. | Private Equity Investor | 30-09-2017 |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners invests in companies located in the United States, France and Europe. The firm targets companies operating in the fields of life sciences and technology sectors. It provides financing for seed and early stage capital requirements. | Private Equity Investor | 30-11-2016 |
Opleiding van Katie Ellias
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
97
Eerstegraads connecties
11
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 11 |
|---|---|
Capillary Biomedical LLC
Capillary Biomedical LLC Medical SpecialtiesHealth Technology Develops medical devices for diabetes management | Health Technology |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners invests in companies located in the United States, France and Europe. The firm targets companies operating in the fields of life sciences and technology sectors. It provides financing for seed and early stage capital requirements. | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Endeavour Vision SA
Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired. | Finance |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
JDRF T1D Fund
JDRF T1D Fund Investment ManagersFinance T1D Fund invests in companies located across the globe. The firm focuses on health technology sector. It participates in early stage capital requirements. | Finance |
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company | Health Technology |
I2o Therapeutics, Inc.
 I2o Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops injection pills for biological therapies | Health Technology |
DiogenX SAS
 DiogenX SAS BiotechnologyHealth Technology Operates as preclinical stage biotech company, that engages in develops and research biologics therapeutics options for diabetic patients | Health Technology |
Tech Health Experts
Tech Health Experts Information Technology ServicesTechnology Services Provides technical support services | Technology Services |
SAB Biotherapeutics, Inc.
 SAB Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in advancing a new class of immunotherapies | Health Technology |
